Get the Stockscreener App
1.53
1.32%
0.02
After Hours:
1.54
0.01
+0.65%
MAIA Biotechnology Inc stock is traded at $1.53, with a volume of 296.61K.
It is up +1.32% in the last 24 hours and up +27.50% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.51
Open:
$1.49
24h Volume:
296.61K
Relative Volume:
0.40
Market Cap:
$56.66M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.1087
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+15.04%
1M Performance:
+27.50%
6M Performance:
-17.30%
1Y Performance:
-25.73%
1-Day Range:
$1.49
$1.57
1-Week Range:
$1.35
$1.66
52-Week Range:
$0.87
$2.74
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.53 | 55.92M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology (MAIA) director granted 24,060 options under 2021 plan - Stock Titan
MAIA Biotechnology (MAIA) director reports grant of 29,216 stock options - Stock Titan
MAIA Biotechnology (MAIA) director receives 25,206 stock options exercisable at $1.53 - Stock Titan
MAIA Biotechnology, Inc. (MAIA) reports 29,789 director stock options at $1.53 - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) reports 24,633 stock options grant - Stock Titan
A stock that deserves closer examination: MAIA Biotechnology Inc (MAIA) - uspostnews.com
MAIA Biotechnology, Inc. Common Stock (NYSE:MAIA) Stock Quote - FinancialContent
MAIA Biotechnology announces open market purchases by CEO, directors - MSN
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Up 144.9% in December - MarketBeat
MAIA Biotechnology (MAIA) Price Target Decreased by 13.32% to 12.38 - MSN
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - The Manila Times
Louie Ngar Yee buys MAIA Biotechnology (MAIA) shares worth $99999 By Investing.com - Investing.com Australia
Stan Smith buys MAIA Biotechnology shares worth $69,999 By Investing.com - Investing.com Canada
Chaouki Steven M buys MAIA Biotechnology shares worth $49999 By Investing.com - Investing.com Australia
Stan Smith buys MAIA Biotechnology shares worth $69,999 - Investing.com
Louie Ngar Yee buys MAIA Biotechnology (MAIA) shares worth $99999 - Investing.com
MAIA Biotechnology Directors Increase Holdings - TradingView — Track All Markets
MAIA (MAIA) director boosts stake with 57,189-share buy and new options - Stock Titan
MAIA Biotechnology (MAIA) director reports stock purchase and new options - Stock Titan
MAIA Biotechnology (MAIA) director reports stock and option purchases - Stock Titan
MAIA Biotechnology, Inc. announced that it has received $1.289791 million in funding - marketscreener.com
Swing Trade: Why hedge funds are buying MAIA Biotechnology Inc stockJuly 2025 Movers & Safe Entry Momentum Stock Tips - moha.gov.vn
MAIA Biotechnology Earnings Notes - Trefis
Can MAIA Biotechnology Inc. stock double in next 5 yearsPortfolio Gains Report & Capital Efficiency Focused Ideas - DonanımHaber
How MAIA Biotechnology Inc. stock compares to industry benchmarksWeekly Profit Summary & AI Forecasted Entry/Exit Points - Улправда
Can MAIA Biotechnology Inc. stock maintain operating marginsJuly 2025 Intraday Action & Expert Approved Momentum Ideas - bolumsonucanavari.com
Why MAIA Biotechnology Inc. stock is upgraded to buy2025 Valuation Update & Daily Growth Stock Tips - DonanımHaber
Can MAIA Biotechnology Inc. stock deliver consistent earnings growth2025 Historical Comparison & Fast Exit/Entry Strategy Plans - Улправда
MAIA Biotechnology, Inc. (MAIA) Gets a Buy from Noble Financial - The Globe and Mail
MAIA Biotechnology announces $2.25M private placement deal - MSN
MAIA Biotechnology Announces $2.25M Private Placement Deal - TipRanks
MAIA Biotechnology (NYSE American: MAIA) details $2.25M private placement - Stock Titan
MAIA Biotechnology Announces $1.51 Million Private Placement - The Manila Times
MAIA Biotechnology, Inc. announced that it expects to receive $1.289791 million in funding - marketscreener.com
MAIA Biotechnology Announces Significant Insider Buying - TipRanks
MAIA Biotechnology, Inc. Announces Key Developments in Cancer Therapy - TradingView — Track All Markets
MAIA Biotechnology (NYSE: MAIA) starts Ateganosine Phase 3 trial and notes insider buying - Stock Titan
MAIA Biotechnology (NYSE American: MAIA) begins Phase 3 NSCLC study of telomere-targeting ateganosine - Stock Titan
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer - Yahoo Finance
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential - Yahoo Finance
MAIA Biotechnology Advances NSCLC Treatment with Ateganosine - TipRanks
MAIA Biotechnology, Inc. Targets $50B Immunotherapy Market with New Approach - TradingView — Track All Markets
MAIA Biotechnology (NYSE: MAIA) highlights $50B immunotherapy market in press release - Stock Titan
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - The Manila Times
Prepare Yourself for Liftoff: MAIA Biotechnology Inc (MAIA) - setenews.com
Director Makes Bold Move with Major Stock Purchase in MAIA Biotechnology! - TipRanks
Dir Smith Buys 13,740 ($16.4K) Of Maia Biotechnology Inc [MAIA] - TradingView — Track All Markets
Can MAIA Biotechnology Inc. stock sustain revenue momentum2025 Price Targets & Real-Time Price Movement Reports - Newser
How MAIA Biotechnology Inc. stock reacts to bond yieldsWeekly Gains Summary & Free Technical Pattern Based Buy Signals - Newser
Vlad Vitoc, Maia Biotech CEO, buys $79,848 in Maia stock By Investing.com - Investing.com Australia
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Cap:
|
Volume (24h):